The advent of anti-HER2 monoclonal antibodies (trastuzumab and lapatinib) has markedly altered the clinical course of both early and advanced HER2-driven breast cancer.  Despite the use of both monoclonal antibodies, patients with HER2-positive breast cancer still experience disease progression, due to resistance.  New data has yielded additional treatment options, and increased the complexity of decision making for the community-based oncologist and patient. 

CME LLC has collaborated with a team of oncology specialists to provide insight into currently unresolved treatment dilemmas. In E-Updates in HER2 Targeting in Breast Cancer, Vol. 3, these experts write about recent advances that are pertinent for oncology practice, and provide a reasoned and practical perspective that may advance patient care.

CME, 2 Credits    Nov 01, 2009

This activity is based on review articles in the journal ONCOLOGY. It is developed from an identified educational need for information about practical management issues in the practice of medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of CME LLC.

CME LLC has collaborated with a team of oncology and hematology specialists to provide insight into currently unresolved treatment dilemmas. In ONCOLOGY, October 2009, these experts write about recent advances that are pertinent for oncology practice, and provide a seasoned and practical perspective that may advance patient care

CME, 3 Credits    Oct 15, 2009

This activity is based on a brief article developed as part of the E-Update series and posted on the Web. It was developed from an identified educational need for information about practical management issues in the practice of medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of CME LLC.

CME, 2 Credits    Oct 15, 2009

This webcast gives a live and interactive review of multiple cases to treat metastatic breast cancer and a case-based discussion on treatment decisions in an environment where there is no single optimal therapy and the patient often has comorbid conditions.

CME, 1 Credits    Oct 15, 2009

CME LLC presents New Perspectives in Metastatic Breast Cancer: An Online Tumor Board Event, where a panel of oncology experts will engage in a case-based discussion, demonstrating how they arrive at treatment decisions in environments where there is no single optimal therapy and the patient often has comorbid conditions.The webcast consisting of multiple cases will provide the community-based oncologist with a greater understanding of how to treat metastatic breast cancer, and provide the learner with access to top thought leaders they normally would not meet.

CME, 1 Credits    Oct 07, 2009

The prevalence of pain and inadequate analgesia in patients with cancer is well documented. Pain management is frequently necessary in cancer treatment, making it critical that those treating the cancer patient completely understand how to correctly assess the pain and determine the proper type of treatment.

CME LLC has collaborated with a team of oncology specialists in the field of pain management. In Managing Cancer Pain: A Bedside Approach, these experts discuss recent advances that are pertinent for oncology practice, and provide a seasoned and practical perspective that may advance patient care.

CME, 1 Credits    Oct 01, 2009

This activity is based on review articles in the journal ONCOLOGY. It is developed from an identified educational need for information about practical management issues in the practice of medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of CME LLC.

CME, 3 Credits    Sep 15, 2009

Changes in our approach to adjuvant therapy in the past decade have been driven by changes in the understanding of breast cancer biology. Genomic analyses suggest that some of our therapeutic interventions, such as hormonal and HER2-targeted therapy, have a solid basis in the cancer cell’s genetic makeup, and also make it clear that breast cancer should be considered a collection of diseases rather than a solitary disease.

CME LLC has collaborated with a team of oncology and hematology specialists to provide insight into currently unresolved treatment dilemmas. In The Adjuvant Treatment of Breast Cancer, these experts write about recent advances that are pertinent for oncology practice, and provide a seasoned and practical perspective that may advance patient care.

CME, 3 Credits    Sep 15, 2009

This activity is based on a brief article developed as part of the E-Update Series and posted on the Web. It was developed from an identified educational need for information about practical management issues in the practice of medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of CME LLC.

CME, 2 Credits    Sep 01, 2009